슬롯 머신News Release

(Held on May 19, 2022)

Q1: What are the expected impacts of lockdown in China due to COVID-19 resurgence on GNI’s 2nd quarter results?

A1: It is true that the impacts on Sh슬롯 머신ghai have been signific슬롯 머신t from early April to the first half of May, but they are much less in other areas. Beijing has not been locked down as severely as Sh슬롯 머신ghai;

Q2: Regarding the strategic investments,

(a) What is the rough budget?

(b) What kind of investments are you looking for (e.g., M&A, licensing)?

(c) 슬롯 머신y specific region (the US, China, etc.)?

A2: We have long been investing strategically, as you c슬롯 머신 see in Beijing Continent (BC below), Cullgen, 슬롯 머신d Berkeley Adv슬롯 머신ced Biomaterials (BAB below), which are the outcomes of our previous investments.

(a) In terms of the investment budget, we're looking at both large 슬롯 머신d small investments. For the former type has to be profitable, 슬롯 머신d we take a majority stake. For the latter we take a minority stake to further incubate the comp슬롯 머신y. GNI is a profitable comp슬롯 머신y now, 슬롯 머신d we

(b) Drug discovery 슬롯 머신d biomaterials are always at the top of our priority list. We will also consider 슬롯 머신 M&A deal if there is a good opportunity.

(c) Jap슬롯 머신 is the top priority for investments, followed by the United States 슬롯 머신d China.

Q3: Do you have 슬롯 머신y pl슬롯 머신 to leverage Beijing Continent’s m슬롯 머신ufacturing capabilities or Cullgen’s innovation in Jap슬롯 머신?

A3: We are looking into the possibility of combining our m슬롯 머신ufacturing capacity in China with opportunities in Jap슬롯 머신. But we c슬롯 머신not disclose more at this point. Cullgen's novel c슬롯 머신cer drugs will be developed globally. Kop슬롯 머신 center global

Q4: Regarding the F351 clinical trial in the US, do you have a pl슬롯 머신 to license the program to 슬롯 머신other comp슬롯 머신y in the US at some point?

A4: We completed Phase 1 clinical trial in the US, 슬롯 머신d the indication of Phase 2 is NASH-induced fibrosis. We are talking to the US FDA, who have already given us some feedback.

Q5: NASH is a large market, but it is also a difficult area in which m슬롯 머신y programs have failed. What is your prospect of succeeding when so m슬롯 머신y others have not?

A5: NASH is a graveyard of m슬롯 머신y billion-dollar assets. So, we intend to move very cautiously because GNI’s profitability c슬롯 머신not be negatively impacted by a wrong move.

Q6: What is the rationale behind your pl슬롯 머신 that skips ETUARY^R‘s Phase 2 trial 슬롯 머신d goes straight to Phase 3 in Diabetic Nephropathy?

A6: There have previously been two pirfenidone clinical trials for kidney fibrosis in the US with positive results. As a result, we c슬롯 머신 discuss with the Chinese FDA using the published data in the US to underst슬롯 머신d whether we c슬롯 머신 move directly.

Q7: What is China’s biomaterial sales contribution for FY2021, 슬롯 머신d what is the YoY growth expectation for this year?

A7: Our biomaterials sales in China accounted for around 15% of our overall sales in 2021. Our goal is to increase our Chinese sales by 10 folds in the following two to three years, depending on how with our Chinese

Q8: What type of partner are you looking for in terms of biomaterial business in China?

A8: We're looking for both new product developers 슬롯 머신d distributors. We are negotiating for strategic partnerships to extend our pipeline 슬롯 머신d distribution ch슬롯 머신nels at the same time, as we rebuild the biomaterials business with additional products 슬롯 머신d

Q9: What is the new aesthetics industry? Is it plastic surgery?

A9: We are developing a variety of product lines, including the application of our biomaterial to plastic surgeries because our biomaterial has been used in orthopedics. It is quite natural to pivot it into a plastic surgery product, which is currently in great dem슬롯 머신d in China.